Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
Matthew L HemmingPatrick BholaMichael A LoycanoJustin A AndersonMadeleine L TaddeiLeona A DoyleElizaveta LavrovaJessica L AndersenKelly S KlegaMorgan R BensonBrian D CromptonChandrajit P RautSuzanne GeorgeAnthony G LetaiGeorge D DemetriEwa SicinskaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our results establish LMS PDX as valuable preclinical models and identify strategies to discover novel vulnerabilities in this disease. These data support the clinical assessment of transcriptional CDK inhibitors as a therapeutic strategy for patients with LMS.